var bibbase_data = {"data":"\"Loading..\"\n\n
\n\n \n\n \n\n \n \n\n \n\n \n \n\n \n\n \n
\n generated by\n \n \"bibbase.org\"\n\n \n
\n \n\n
\n\n \n\n\n
\n\n Excellent! Next you can\n create a new website with this list, or\n embed it in an existing web page by copying & pasting\n any of the following snippets.\n\n
\n JavaScript\n (easiest)\n
\n \n <script src=\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fusers%2F6607533%2Fcollections%2F5DDKZMY6%2Fitems%3Fkey%3DhGXLq241MCQA3ow7rlTIV2gY%26format%3Dbibtex%26limit%3D100&jsonp=1&jsonp=1\"></script>\n \n
\n\n PHP\n
\n \n <?php\n $contents = file_get_contents(\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fusers%2F6607533%2Fcollections%2F5DDKZMY6%2Fitems%3Fkey%3DhGXLq241MCQA3ow7rlTIV2gY%26format%3Dbibtex%26limit%3D100&jsonp=1\");\n print_r($contents);\n ?>\n \n
\n\n iFrame\n (not recommended)\n
\n \n <iframe src=\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fusers%2F6607533%2Fcollections%2F5DDKZMY6%2Fitems%3Fkey%3DhGXLq241MCQA3ow7rlTIV2gY%26format%3Dbibtex%26limit%3D100&jsonp=1\"></iframe>\n \n
\n\n

\n For more details see the documention.\n

\n
\n
\n\n
\n\n This is a preview! To use this list on your own web site\n or create a new web site from it,\n create a free account. The file will be added\n and you will be able to edit it in the File Manager.\n We will show you instructions once you've created your account.\n
\n\n
\n\n

To the site owner:

\n\n

Action required! Mendeley is changing its\n API. In order to keep using Mendeley with BibBase past April\n 14th, you need to:\n

    \n
  1. renew the authorization for BibBase on Mendeley, and
  2. \n
  3. update the BibBase URL\n in your page the same way you did when you initially set up\n this page.\n
  4. \n
\n

\n\n

\n \n \n Fix it now\n

\n
\n\n
\n\n\n
\n \n \n
\n
\n  \n 2021\n \n \n (15)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Asthma and COVID-19: Preconceptions about Predisposition.\n \n \n \n \n\n\n \n Beasley, R.; Hills, T.; and Kearns, N.\n\n\n \n\n\n\n American Journal of Respiratory and Critical Care Medicine, 203(7): 799–801. April 2021.\n \n\n\n\n
\n\n\n\n \n \n \"AsthmaPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 2 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{beasley_asthma_2021,\n\ttitle = {Asthma and {COVID}-19: {Preconceptions} about {Predisposition}},\n\tvolume = {203},\n\tissn = {1073-449X, 1535-4970},\n\tshorttitle = {Asthma and {COVID}-19},\n\turl = {https://www.atsjournals.org/doi/10.1164/rccm.202102-0266ED},\n\tdoi = {10.1164/rccm.202102-0266ED},\n\tlanguage = {en},\n\tnumber = {7},\n\turldate = {2022-03-04},\n\tjournal = {American Journal of Respiratory and Critical Care Medicine},\n\tauthor = {Beasley, Richard and Hills, Thomas and Kearns, Nethmi},\n\tmonth = apr,\n\tyear = {2021},\n\tpages = {799--801},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Charting a course for the management of long COVID.\n \n \n \n \n\n\n \n Beasley, R.; Kearns, N.; and Hills, T.\n\n\n \n\n\n\n The Lancet Respiratory Medicine, 9(12): 1358–1360. December 2021.\n \n\n\n\n
\n\n\n\n \n \n \"ChartingPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{beasley_charting_2021,\n\ttitle = {Charting a course for the management of long {COVID}},\n\tvolume = {9},\n\tissn = {22132600},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2213260021003143},\n\tdoi = {10.1016/S2213-2600(21)00314-3},\n\tlanguage = {en},\n\tnumber = {12},\n\turldate = {2022-03-04},\n\tjournal = {The Lancet Respiratory Medicine},\n\tauthor = {Beasley, Richard and Kearns, Nethmi and Hills, Tom},\n\tmonth = dec,\n\tyear = {2021},\n\tpages = {1358--1360},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n COVID-19 border controls prevent a 2021 seasonal influenza epidemic in New Zealand.\n \n \n \n \n\n\n \n Hills, T.; Hatter, L.; Kearns, N.; Bruce, P.; and Beasley, R.\n\n\n \n\n\n\n Public Health, 200: e6–e7. November 2021.\n \n\n\n\n
\n\n\n\n \n \n \"COVID-19Paper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{hills_covid-19_2021,\n\ttitle = {{COVID}-19 border controls prevent a 2021 seasonal influenza epidemic in {New} {Zealand}},\n\tvolume = {200},\n\tissn = {00333506},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S0033350621003607},\n\tdoi = {10.1016/j.puhe.2021.09.013},\n\tlanguage = {en},\n\turldate = {2022-03-04},\n\tjournal = {Public Health},\n\tauthor = {Hills, T. and Hatter, L. and Kearns, N. and Bruce, P. and Beasley, R.},\n\tmonth = nov,\n\tyear = {2021},\n\tpages = {e6--e7},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.\n \n \n \n \n\n\n \n Arabi, Y. M.; Gordon, A. C.; and Investigators\", \". R.\n\n\n \n\n\n\n Intensive Care Medicine, 47(8): 867–886. August 2021.\n \n\n\n\n
\n\n\n\n \n \n \"Lopinavir-ritonavirPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{arabi_lopinavir-ritonavir_2021,\n\ttitle = {Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with {COVID}-19: {REMAP}-{CAP} randomized controlled trial},\n\tvolume = {47},\n\tissn = {0342-4642, 1432-1238},\n\tshorttitle = {Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with {COVID}-19},\n\turl = {https://link.springer.com/10.1007/s00134-021-06448-5},\n\tdoi = {10.1007/s00134-021-06448-5},\n\tlanguage = {en},\n\tnumber = {8},\n\turldate = {2021-10-02},\n\tjournal = {Intensive Care Medicine},\n\tauthor = {Arabi, Yaseen M. and Gordon, Anthony C. and "the REMAP-CAP Investigators"},\n\tmonth = aug,\n\tyear = {2021},\n\tpages = {867--886},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Respiratory syncytial virus: paying the immunity debt with interest.\n \n \n \n \n\n\n \n Hatter, L.; Eathorne, A.; Hills, T.; Bruce, P.; and Beasley, R.\n\n\n \n\n\n\n The Lancet Child & Adolescent Health,S2352464221003333. October 2021.\n \n\n\n\n
\n\n\n\n \n \n \"RespiratoryPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{hatter_respiratory_2021,\n\ttitle = {Respiratory syncytial virus: paying the immunity debt with interest},\n\tissn = {23524642},\n\tshorttitle = {Respiratory syncytial virus},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2352464221003333},\n\tdoi = {10.1016/S2352-4642(21)00333-3},\n\tlanguage = {en},\n\turldate = {2021-10-28},\n\tjournal = {The Lancet Child \\& Adolescent Health},\n\tauthor = {Hatter, Lee and Eathorne, Allie and Hills, Thomas and Bruce, Pepa and Beasley, Richard},\n\tmonth = oct,\n\tyear = {2021},\n\tpages = {S2352464221003333},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Charting a course for the management of long COVID.\n \n \n \n \n\n\n \n Beasley, R.; Kearns, N.; and Hills, T.\n\n\n \n\n\n\n The Lancet Respiratory Medicine,S2213260021003143. August 2021.\n \n\n\n\n
\n\n\n\n \n \n \"ChartingPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{beasley_charting_2021-1,\n\ttitle = {Charting a course for the management of long {COVID}},\n\tissn = {22132600},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2213260021003143},\n\tdoi = {10.1016/S2213-2600(21)00314-3},\n\tlanguage = {en},\n\turldate = {2021-10-02},\n\tjournal = {The Lancet Respiratory Medicine},\n\tauthor = {Beasley, Richard and Kearns, Nethmi and Hills, Tom},\n\tmonth = aug,\n\tyear = {2021},\n\tpages = {S2213260021003143},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n COVID-19 border controls prevent a 2021 seasonal influenza epidemic in New Zealand.\n \n \n \n \n\n\n \n Hills, T.; Hatter, L.; Kearns, N.; Bruce, P.; and Beasley, R.\n\n\n \n\n\n\n Public Health,S0033350621003607. September 2021.\n \n\n\n\n
\n\n\n\n \n \n \"COVID-19Paper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{hills_covid-19_2021-1,\n\ttitle = {{COVID}-19 border controls prevent a 2021 seasonal influenza epidemic in {New} {Zealand}},\n\tissn = {00333506},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S0033350621003607},\n\tdoi = {10.1016/j.puhe.2021.09.013},\n\tlanguage = {en},\n\turldate = {2021-09-29},\n\tjournal = {Public Health},\n\tauthor = {Hills, Thomas and Hatter, Lee and Kearns, Nethmi and Bruce, Pepa and Beasley, Richard},\n\tmonth = sep,\n\tyear = {2021},\n\tpages = {S0033350621003607},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Clinical and epidemiological characteristics of COVID-19 in Wellington, New Zealand: a retrospective, observational study.\n \n \n \n \n\n\n \n Kearns, N.; Eathorne, A.; Luff, T.; Kearns, C.; Thornley, C.; Semprini, A.; Beasley, R.; and Nesdale, A.\n\n\n \n\n\n\n New Zealand Medical Journal, 134(1542): 38–49. September 2021.\n \n\n\n\n
\n\n\n\n \n \n \"ClinicalPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{kearns_clinical_2021,\n\ttitle = {Clinical and epidemiological characteristics of {COVID}-19 in {Wellington}, {New} {Zealand}: a retrospective, observational study},\n\tvolume = {134},\n\tissn = {1175-8716},\n\turl = {https://journal.nzma.org.nz/journal-articles/clinical-and-epidemiological-characteristics-of-covid-19-in-wellington-new-zealand-a-retrospective-observational-study},\n\tnumber = {1542},\n\turldate = {2021-09-17},\n\tjournal = {New Zealand Medical Journal},\n\tauthor = {Kearns, Nethmi and Eathorne, Allie and Luff, Tessa and Kearns, Ciléin and Thornley, Craig and Semprini, Alex and Beasley, Richard and Nesdale, Annette},\n\tmonth = sep,\n\tyear = {2021},\n\tpages = {38--49},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Reduced mortality in New Zealand during the COVID-19 pandemic.\n \n \n \n \n\n\n \n Kung, S.; Doppen, M.; Black, M.; Hills, T.; and Kearns, N.\n\n\n \n\n\n\n The Lancet, 397(10268): 25. January 2021.\n \n\n\n\n
\n\n\n\n \n \n \"ReducedPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{kung_reduced_2021,\n\ttitle = {Reduced mortality in {New} {Zealand} during the {COVID}-19 pandemic},\n\tvolume = {397},\n\tissn = {01406736},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S0140673620326477},\n\tdoi = {10.1016/S0140-6736(20)32647-7},\n\tlanguage = {en},\n\tnumber = {10268},\n\turldate = {2021-04-30},\n\tjournal = {The Lancet},\n\tauthor = {Kung, Stacey and Doppen, Marjan and Black, Melissa and Hills, Tom and Kearns, Nethmi},\n\tmonth = jan,\n\tyear = {2021},\n\tpages = {25},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Regulatory action to protect access to hydroxychloroquine for approved rheumatic indications during COVID‐19 in New Zealand.\n \n \n \n \n\n\n \n Duffy, E.; Arroll, N.; Beasley, R.; and Hills, T.\n\n\n \n\n\n\n Arthritis & Rheumatology,art.41643. March 2021.\n \n\n\n\n
\n\n\n\n \n \n \"RegulatoryPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{duffy_regulatory_2021,\n\ttitle = {Regulatory action to protect access to hydroxychloroquine for approved rheumatic indications during {COVID}‐19 in {New} {Zealand}},\n\tissn = {2326-5191, 2326-5205},\n\turl = {https://onlinelibrary.wiley.com/doi/10.1002/art.41643},\n\tdoi = {10.1002/art.41643},\n\tlanguage = {en},\n\turldate = {2021-04-28},\n\tjournal = {Arthritis \\& Rheumatology},\n\tauthor = {Duffy, Eamon and Arroll, Nicola and Beasley, Richard and Hills, Thomas},\n\tmonth = mar,\n\tyear = {2021},\n\tpages = {art.41643},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Asthma and COVID-19: Preconceptions about Predisposition.\n \n \n \n \n\n\n \n Beasley, R.; Hills, T.; and Kearns, N.\n\n\n \n\n\n\n American Journal of Respiratory and Critical Care Medicine, 203(7): 799–801. April 2021.\n \n\n\n\n
\n\n\n\n \n \n \"AsthmaPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 2 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{beasley_asthma_2021-1,\n\ttitle = {Asthma and {COVID}-19: {Preconceptions} about {Predisposition}},\n\tvolume = {203},\n\tissn = {1073-449X, 1535-4970},\n\tshorttitle = {Asthma and {COVID}-19},\n\turl = {https://www.atsjournals.org/doi/10.1164/rccm.202102-0266ED},\n\tdoi = {10.1164/rccm.202102-0266ED},\n\tlanguage = {en},\n\tnumber = {7},\n\turldate = {2021-04-28},\n\tjournal = {American Journal of Respiratory and Critical Care Medicine},\n\tauthor = {Beasley, Richard and Hills, Thomas and Kearns, Nethmi},\n\tmonth = apr,\n\tyear = {2021},\n\tpages = {799--801},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.\n \n \n \n \n\n\n \n Axfors, C.; Schmitt, A. M.; Janiaud, P.; van’t Hooft, J.; Abd-Elsalam, S.; Abdo, E. F.; Abella, B. S.; Akram, J.; Amaravadi, R. K.; Angus, D. C.; Arabi, Y. M.; Azhar, S.; Baden, L. R.; Baker, A. W.; Belkhir, L.; Benfield, T.; Berrevoets, M. A. H.; Chen, C.; Chen, T.; Cheng, S.; Cheng, C.; Chung, W.; Cohen, Y. Z.; Cowan, L. N.; Dalgard, O.; de Almeida e Val, F. F.; de Lacerda, M. V. G.; de Melo, G. C.; Derde, L.; Dubee, V.; Elfakir, A.; Gordon, A. C.; Hernandez-Cardenas, C. M.; Hills, T.; Hoepelman, A. I. M.; Huang, Y.; Igau, B.; Jin, R.; Jurado-Camacho, F.; Khan, K. S.; Kremsner, P. G.; Kreuels, B.; Kuo, C.; Le, T.; Lin, Y.; Lin, W.; Lin, T.; Lyngbakken, M. N.; McArthur, C.; McVerry, B. J.; Meza-Meneses, P.; Monteiro, W. M.; Morpeth, S. C.; Mourad, A.; Mulligan, M. J.; Murthy, S.; Naggie, S.; Narayanasamy, S.; Nichol, A.; Novack, L. A.; O’Brien, S. M.; Okeke, N. L.; Perez, L.; Perez-Padilla, R.; Perrin, L.; Remigio-Luna, A.; Rivera-Martinez, N. E.; Rockhold, F. W.; Rodriguez-Llamazares, S.; Rolfe, R.; Rosa, R.; Røsjø, H.; Sampaio, V. S.; Seto, T. B.; Shehzad, M.; Soliman, S.; Stout, J. E.; Thirion-Romero, I.; Troxel, A. B.; Tseng, T.; Turner, N. A.; Ulrich, R. J.; Walsh, S. R.; Webb, S. A.; Weehuizen, J. M.; Velinova, M.; Wong, H.; Wrenn, R.; Zampieri, F. G.; Zhong, W.; Moher, D.; Goodman, S. N.; Ioannidis, J. P. A.; and Hemkens, L. G.\n\n\n \n\n\n\n Nature Communications, 12(1): 2349. December 2021.\n \n\n\n\n
\n\n\n\n \n \n \"MortalityPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{axfors_mortality_2021,\n\ttitle = {Mortality outcomes with hydroxychloroquine and chloroquine in {COVID}-19 from an international collaborative meta-analysis of randomized trials},\n\tvolume = {12},\n\tissn = {2041-1723},\n\turl = {http://www.nature.com/articles/s41467-021-22446-z},\n\tdoi = {10.1038/s41467-021-22446-z},\n\tabstract = {Abstract\n            \n              Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or early discontinuation. We aim to estimate the effects of hydroxychloroquine and chloroquine on survival in COVID-19 from all currently available RCT evidence, published and unpublished. We present a rapid meta-analysis of ongoing, completed, or discontinued RCTs on hydroxychloroquine or chloroquine treatment for any COVID-19 patients (protocol:\n              https://osf.io/QESV4/\n              ). We systematically identified unpublished RCTs (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, Cochrane COVID-registry up to June 11, 2020), and published RCTs (PubMed, medRxiv and bioRxiv up to October 16, 2020). All-cause mortality has been extracted (publications/preprints) or requested from investigators and combined in random-effects meta-analyses, calculating odds ratios (ORs) with 95\\% confidence intervals (CIs), separately for hydroxychloroquine and chloroquine. Prespecified subgroup analyses include patient setting, diagnostic confirmation, control type, and publication status. Sixty-three trials were potentially eligible. We included 14 unpublished trials (1308 patients) and 14 publications/preprints (9011 patients). Results for hydroxychloroquine are dominated by RECOVERY and WHO SOLIDARITY, two highly pragmatic trials, which employed relatively high doses and included 4716 and 1853 patients, respectively (67\\% of the total sample size). The combined OR on all-cause mortality for hydroxychloroquine is 1.11 (95\\% CI: 1.02, 1.20; I² = 0\\%; 26 trials; 10,012 patients) and for chloroquine 1.77 (95\\%CI: 0.15, 21.13, I² = 0\\%; 4 trials; 307 patients). We identified no subgroup effects. We found that treatment with hydroxychloroquine is associated with increased mortality in COVID-19 patients, and there is no benefit of chloroquine. Findings have unclear generalizability to outpatients, children, pregnant women, and people with comorbidities.},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2021-04-28},\n\tjournal = {Nature Communications},\n\tauthor = {Axfors, Cathrine and Schmitt, Andreas M. and Janiaud, Perrine and van’t Hooft, Janneke and Abd-Elsalam, Sherief and Abdo, Ehab F. and Abella, Benjamin S. and Akram, Javed and Amaravadi, Ravi K. and Angus, Derek C. and Arabi, Yaseen M. and Azhar, Shehnoor and Baden, Lindsey R. and Baker, Arthur W. and Belkhir, Leila and Benfield, Thomas and Berrevoets, Marvin A. H. and Chen, Cheng-Pin and Chen, Tsung-Chia and Cheng, Shu-Hsing and Cheng, Chien-Yu and Chung, Wei-Sheng and Cohen, Yehuda Z. and Cowan, Lisa N. and Dalgard, Olav and de Almeida e Val, Fernando F. and de Lacerda, Marcus V. G. and de Melo, Gisely C. and Derde, Lennie and Dubee, Vincent and Elfakir, Anissa and Gordon, Anthony C. and Hernandez-Cardenas, Carmen M. and Hills, Thomas and Hoepelman, Andy I. M. and Huang, Yi-Wen and Igau, Bruno and Jin, Ronghua and Jurado-Camacho, Felipe and Khan, Khalid S. and Kremsner, Peter G. and Kreuels, Benno and Kuo, Cheng-Yu and Le, Thuy and Lin, Yi-Chun and Lin, Wu-Pu and Lin, Tse-Hung and Lyngbakken, Magnus Nakrem and McArthur, Colin and McVerry, Bryan J. and Meza-Meneses, Patricia and Monteiro, Wuelton M. and Morpeth, Susan C. and Mourad, Ahmad and Mulligan, Mark J. and Murthy, Srinivas and Naggie, Susanna and Narayanasamy, Shanti and Nichol, Alistair and Novack, Lewis A. and O’Brien, Sean M. and Okeke, Nwora Lance and Perez, Léna and Perez-Padilla, Rogelio and Perrin, Laurent and Remigio-Luna, Arantxa and Rivera-Martinez, Norma E. and Rockhold, Frank W. and Rodriguez-Llamazares, Sebastian and Rolfe, Robert and Rosa, Rossana and Røsjø, Helge and Sampaio, Vanderson S. and Seto, Todd B. and Shehzad, Muhammad and Soliman, Shaimaa and Stout, Jason E. and Thirion-Romero, Ireri and Troxel, Andrea B. and Tseng, Ting-Yu and Turner, Nicholas A. and Ulrich, Robert J. and Walsh, Stephen R. and Webb, Steve A. and Weehuizen, Jesper M. and Velinova, Maria and Wong, Hon-Lai and Wrenn, Rebekah and Zampieri, Fernando G. and Zhong, Wu and Moher, David and Goodman, Steven N. and Ioannidis, John P. A. and Hemkens, Lars G.},\n\tmonth = dec,\n\tyear = {2021},\n\tpages = {2349},\n}\n\n
\n
\n\n\n
\n Abstract Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or early discontinuation. We aim to estimate the effects of hydroxychloroquine and chloroquine on survival in COVID-19 from all currently available RCT evidence, published and unpublished. We present a rapid meta-analysis of ongoing, completed, or discontinued RCTs on hydroxychloroquine or chloroquine treatment for any COVID-19 patients (protocol: https://osf.io/QESV4/ ). We systematically identified unpublished RCTs (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, Cochrane COVID-registry up to June 11, 2020), and published RCTs (PubMed, medRxiv and bioRxiv up to October 16, 2020). All-cause mortality has been extracted (publications/preprints) or requested from investigators and combined in random-effects meta-analyses, calculating odds ratios (ORs) with 95% confidence intervals (CIs), separately for hydroxychloroquine and chloroquine. Prespecified subgroup analyses include patient setting, diagnostic confirmation, control type, and publication status. Sixty-three trials were potentially eligible. We included 14 unpublished trials (1308 patients) and 14 publications/preprints (9011 patients). Results for hydroxychloroquine are dominated by RECOVERY and WHO SOLIDARITY, two highly pragmatic trials, which employed relatively high doses and included 4716 and 1853 patients, respectively (67% of the total sample size). The combined OR on all-cause mortality for hydroxychloroquine is 1.11 (95% CI: 1.02, 1.20; I² = 0%; 26 trials; 10,012 patients) and for chloroquine 1.77 (95%CI: 0.15, 21.13, I² = 0%; 4 trials; 307 patients). We identified no subgroup effects. We found that treatment with hydroxychloroquine is associated with increased mortality in COVID-19 patients, and there is no benefit of chloroquine. Findings have unclear generalizability to outpatients, children, pregnant women, and people with comorbidities.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Operationalisation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 trials in a low and lower-middle income critical care learning health system.\n \n \n \n \n\n\n \n Aryal, D.; Beane, A.; Dondorp, A. M.; Green, C.; Haniffa, R.; Hashmi, M.; Jayakumar, D.; Marshall, J. C.; McArthur, C. J.; Murthy, S.; Webb, S. A.; Acharya, S. P.; Ishani, P. G. P.; Jawad, I.; Khanal, S.; Koirala, K.; Luitel, S.; Pabasara, U.; Paneru, H. R.; Kumar, A.; Patel, S. S.; Ramakrishnan, N.; Salahuddin, N.; Shaikh, M.; Tolppa, T.; Udayanga, I.; and Umrani, Z.\n\n\n \n\n\n\n Wellcome Open Research, 6: 14. January 2021.\n \n\n\n\n
\n\n\n\n \n \n \"OperationalisationPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{aryal_operationalisation_2021,\n\ttitle = {Operationalisation of the {Randomized} {Embedded} {Multifactorial} {Adaptive} {Platform} for {COVID}-19 trials in a low and lower-middle income critical care learning health system.},\n\tvolume = {6},\n\tissn = {2398-502X},\n\turl = {https://wellcomeopenresearch.org/articles/6-14/v1},\n\tdoi = {10.12688/wellcomeopenres.16486.1},\n\tabstract = {The Randomized Embedded Multifactorial Adaptive Platform (REMAP-CAP) adapted for COVID-19) trial is a global adaptive platform trial of hospitalised patients with COVID-19. We describe implementation in three countries under the umbrella of the Wellcome supported Low and Middle Income Country (LMIC) critical  care network: Collaboration for Research, Implementation and Training in Asia (CCA). The collaboration sought to overcome known barriers to multi centre-clinical trials in resource-limited settings. Methods described focused on six aspects of implementation: i, Strengthening an existing community of practice; ii, Remote study site recruitment, training and support; iii, Harmonising the REMAP CAP- COVID trial with existing care processes; iv, Embedding REMAP CAP- COVID case report form into the existing CCA registry platform, v, Context specific adaptation and data management; vi, Alignment with existing pandemic and critical care research in the CCA. Methods described here may enable other LMIC sites to participate as equal partners in international critical care trials of urgent public health importance, both during this pandemic and beyond.},\n\tlanguage = {en},\n\turldate = {2021-04-28},\n\tjournal = {Wellcome Open Research},\n\tauthor = {Aryal, Diptesh and Beane, Abi and Dondorp, Arjen M. and Green, Cameron and Haniffa, Rashan and Hashmi, Madiha and Jayakumar, Devachandran and Marshall, John C. and McArthur, Colin J. and Murthy, Srinivas and Webb, Steven A. and Acharya, Subhash P. and Ishani, Pramodya G. P. and Jawad, Issrah and Khanal, Sushil and Koirala, Kanchan and Luitel, Subekshya and Pabasara, Upulee and Paneru, Hem Raj and Kumar, Ashok and Patel, Shoaib Siddiq and Ramakrishnan, Nagarajan and Salahuddin, Nawal and Shaikh, Mohiuddin and Tolppa, Timo and Udayanga, Ishara and Umrani, Zulfiqar},\n\tmonth = jan,\n\tyear = {2021},\n\tpages = {14},\n}\n\n
\n
\n\n\n
\n The Randomized Embedded Multifactorial Adaptive Platform (REMAP-CAP) adapted for COVID-19) trial is a global adaptive platform trial of hospitalised patients with COVID-19. We describe implementation in three countries under the umbrella of the Wellcome supported Low and Middle Income Country (LMIC) critical  care network: Collaboration for Research, Implementation and Training in Asia (CCA). The collaboration sought to overcome known barriers to multi centre-clinical trials in resource-limited settings. Methods described focused on six aspects of implementation: i, Strengthening an existing community of practice; ii, Remote study site recruitment, training and support; iii, Harmonising the REMAP CAP- COVID trial with existing care processes; iv, Embedding REMAP CAP- COVID case report form into the existing CCA registry platform, v, Context specific adaptation and data management; vi, Alignment with existing pandemic and critical care research in the CCA. Methods described here may enable other LMIC sites to participate as equal partners in international critical care trials of urgent public health importance, both during this pandemic and beyond.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.\n \n \n \n \n\n\n \n The REMAP-CAP Investigators\n\n\n \n\n\n\n New England Journal of Medicine,NEJMoa2100433. February 2021.\n \n\n\n\n
\n\n\n\n \n \n \"Interleukin-6Paper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{the_remap-cap_investigators_interleukin-6_2021,\n\ttitle = {Interleukin-6 {Receptor} {Antagonists} in {Critically} {Ill} {Patients} with {Covid}-19},\n\tissn = {0028-4793, 1533-4406},\n\turl = {http://www.nejm.org/doi/10.1056/NEJMoa2100433},\n\tdoi = {10.1056/NEJMoa2100433},\n\tlanguage = {en},\n\turldate = {2021-02-28},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {{The REMAP-CAP Investigators}},\n\tmonth = feb,\n\tyear = {2021},\n\tpages = {NEJMoa2100433},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Underestimation of COVID-19 mortality during the pandemic.\n \n \n \n \n\n\n \n Kung, S.; Doppen, M.; Black, M.; Braithwaite, I.; Kearns, C.; Weatherall, M.; Beasley, R.; and Kearns, N.\n\n\n \n\n\n\n ERJ Open Research, 7(1): 00766–2020. January 2021.\n Number: 1\n\n\n\n
\n\n\n\n \n \n \"UnderestimationPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{kung_underestimation_2021,\n\ttitle = {Underestimation of {COVID}-19 mortality during the pandemic},\n\tvolume = {7},\n\tissn = {2312-0541},\n\turl = {http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00766-2020},\n\tdoi = {10.1183/23120541.00766-2020},\n\tabstract = {Background\n              There has been considerable international variation in mortality during the COVID-19 pandemic. The objective of this study was to investigate the differences between mortality registered as due to COVID-19 and the excess all-cause mortality reported in countries worldwide during the COVID-19 pandemic.\n            \n            \n              Methods\n              Ecological analysis of 22 countries compared 5-year historical all-cause mortality, reported all-cause mortality and expected all-cause mortality (calculated as historical mortality plus the reported deaths attributed to COVID-19). Data available from the first week of January 2020 to that most recently available were analysed.\n            \n            \n              Results\n              Compared to the preceding 5 years, there was an excess of 716 616 deaths, of which 64.3\\% were attributed to COVID-19. The proportion of deaths registered as COVID-19-related/excess deaths varied markedly between countries, ranging between 30\\% and 197\\% in those countries that had an excess of deaths during the period of observation. In most countries where a definite peak in COVID-19-related deaths occurred, the increase in reported all-cause mortality preceded the increase in COVID-19 reported mortality. During the latter period of observation, a few countries reported fewer all-cause deaths than the historical figures.\n            \n            \n              Conclusion\n              The increases in all-cause mortality preceded the increase in COVID-19 mortality in most countries that had definite spikes in COVID-19 mortality. The number of deaths attributed to COVID-19 was underestimated by at least 35\\%. Together these findings suggest that calculation of excess all-cause mortality is a better predictor of COVID-19 mortality than the reported rates, in those countries experiencing definite increases in mortality.},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2021-02-18},\n\tjournal = {ERJ Open Research},\n\tauthor = {Kung, Stacey and Doppen, Marjan and Black, Melissa and Braithwaite, Irene and Kearns, Ciléin and Weatherall, Mark and Beasley, Richard and Kearns, Nethmi},\n\tmonth = jan,\n\tyear = {2021},\n\tnote = {Number: 1},\n\tpages = {00766--2020},\n}\n\n
\n
\n\n\n
\n Background There has been considerable international variation in mortality during the COVID-19 pandemic. The objective of this study was to investigate the differences between mortality registered as due to COVID-19 and the excess all-cause mortality reported in countries worldwide during the COVID-19 pandemic. Methods Ecological analysis of 22 countries compared 5-year historical all-cause mortality, reported all-cause mortality and expected all-cause mortality (calculated as historical mortality plus the reported deaths attributed to COVID-19). Data available from the first week of January 2020 to that most recently available were analysed. Results Compared to the preceding 5 years, there was an excess of 716 616 deaths, of which 64.3% were attributed to COVID-19. The proportion of deaths registered as COVID-19-related/excess deaths varied markedly between countries, ranging between 30% and 197% in those countries that had an excess of deaths during the period of observation. In most countries where a definite peak in COVID-19-related deaths occurred, the increase in reported all-cause mortality preceded the increase in COVID-19 reported mortality. During the latter period of observation, a few countries reported fewer all-cause deaths than the historical figures. Conclusion The increases in all-cause mortality preceded the increase in COVID-19 mortality in most countries that had definite spikes in COVID-19 mortality. The number of deaths attributed to COVID-19 was underestimated by at least 35%. Together these findings suggest that calculation of excess all-cause mortality is a better predictor of COVID-19 mortality than the reported rates, in those countries experiencing definite increases in mortality.\n
\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2020\n \n \n (3)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Frailty and mortality in patients with COVID-19.\n \n \n \n \n\n\n \n Darvall, J. N; Bellomo, R.; Young, P. J; Rockwood, K.; and Pilcher, D.\n\n\n \n\n\n\n The Lancet Public Health, 5(11): e580. November 2020.\n \n\n\n\n
\n\n\n\n \n \n \"FrailtyPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{darvall_frailty_2020,\n\ttitle = {Frailty and mortality in patients with {COVID}-19},\n\tvolume = {5},\n\tissn = {24682667},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2468266720302280},\n\tdoi = {10.1016/S2468-2667(20)30228-0},\n\tlanguage = {en},\n\tnumber = {11},\n\turldate = {2021-05-07},\n\tjournal = {The Lancet Public Health},\n\tauthor = {Darvall, Jai N and Bellomo, Rinaldo and Young, Paul J and Rockwood, Kenneth and Pilcher, David},\n\tmonth = nov,\n\tyear = {2020},\n\tpages = {e580},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Underestimation of COVID-19 mortality during the pandemic.\n \n \n \n \n\n\n \n Kung, S.; Doppen, M.; Black, M.; Braithwaite, I.; Kearns, C.; Weatherall, M.; Beasley, R.; and Kearns, N.\n\n\n \n\n\n\n ERJ Open Research,00766–2020. December 2020.\n \n\n\n\n
\n\n\n\n \n \n \"UnderestimationPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{kung_underestimation_2020,\n\ttitle = {Underestimation of {COVID}-19 mortality during the pandemic},\n\tissn = {2312-0541},\n\turl = {http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00766-2020},\n\tdoi = {10.1183/23120541.00766-2020},\n\tabstract = {Background\n              There has been considerable international variation in mortality during the COVID-19 pandemic. The objective of this study was to investigate the differences between mortality registered as due to COVID-19 and the excess all-cause mortality reported in countries worldwide during the COVID-19 pandemic.\n            \n            \n              Methods\n              Ecological analysis of 22 countries compared five-year historical all-cause mortality, reported all-cause mortality and expected all-cause mortality (calculated as the historical mortality plus the reported deaths attributed to COVID-19). Data available from the first week of January 2020 to that most recently available were analysed.\n            \n            \n              Results\n              Compared to the preceding five years, there was an excess of 716 616 deaths of which 64.3\\% were attributed to COVID-19. The proportion of deaths registered as COVID-19 related/excess deaths varied markedly between countries, ranging between 30\\% and 197\\% in those countries that had an excess of deaths during the period of observation. In most countries where a definite peak in COVID-19 related deaths occurred, the increase in reported all-cause mortality preceded the increase in COVID-19 reported mortality. During the latter period of observation, a few countries reported fewer all-cause deaths than the historical figures.\n            \n            \n              Conclusion\n              The increases in all-cause mortality preceded the increase in COVID-19 mortality in most countries that had definite spikes in COVID-19 mortality. The number of deaths attributed to COVID-19 was underestimated by at least 35\\%. Together these findings suggest that calculation of excess all-cause mortality is a better predictor of COVID-19 mortality than the reported rates, in those countries experiencing definite increases in mortality.},\n\tlanguage = {en},\n\turldate = {2021-01-12},\n\tjournal = {ERJ Open Research},\n\tauthor = {Kung, Stacey and Doppen, Marjan and Black, Melissa and Braithwaite, Irene and Kearns, Ciléin and Weatherall, Mark and Beasley, Richard and Kearns, Nethmi},\n\tmonth = dec,\n\tyear = {2020},\n\tpages = {00766--2020},\n}\n\n
\n
\n\n\n
\n Background There has been considerable international variation in mortality during the COVID-19 pandemic. The objective of this study was to investigate the differences between mortality registered as due to COVID-19 and the excess all-cause mortality reported in countries worldwide during the COVID-19 pandemic. Methods Ecological analysis of 22 countries compared five-year historical all-cause mortality, reported all-cause mortality and expected all-cause mortality (calculated as the historical mortality plus the reported deaths attributed to COVID-19). Data available from the first week of January 2020 to that most recently available were analysed. Results Compared to the preceding five years, there was an excess of 716 616 deaths of which 64.3% were attributed to COVID-19. The proportion of deaths registered as COVID-19 related/excess deaths varied markedly between countries, ranging between 30% and 197% in those countries that had an excess of deaths during the period of observation. In most countries where a definite peak in COVID-19 related deaths occurred, the increase in reported all-cause mortality preceded the increase in COVID-19 reported mortality. During the latter period of observation, a few countries reported fewer all-cause deaths than the historical figures. Conclusion The increases in all-cause mortality preceded the increase in COVID-19 mortality in most countries that had definite spikes in COVID-19 mortality. The number of deaths attributed to COVID-19 was underestimated by at least 35%. Together these findings suggest that calculation of excess all-cause mortality is a better predictor of COVID-19 mortality than the reported rates, in those countries experiencing definite increases in mortality.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Influenza control during the COVID-19 pandemic.\n \n \n \n \n\n\n \n Hills, T.; Kearns, N.; Kearns, C.; and Beasley, R.\n\n\n \n\n\n\n The Lancet. October 2020.\n \n\n\n\n
\n\n\n\n \n \n \"InfluenzaPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 2 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n
@article{hills_influenza_2020,\n\ttitle = {Influenza control during the {COVID}-19 pandemic},\n\turl = {https://doi.org/10.1016/S0140-6736(20)32166-8},\n\turldate = {2020-10-23},\n\tjournal = {The Lancet},\n\tauthor = {Hills, Thomas and Kearns, Nethmi and Kearns, Ciléin and Beasley, Richard},\n\tmonth = oct,\n\tyear = {2020},\n}\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n\n\n\n
\n\n\n \n\n \n \n \n \n\n
\n"}; document.write(bibbase_data.data);